Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

Second primary malignancies after CAR T-cell therapy: causal attribution, clonal evolution, and risk-adapted surveillance

  1. 1Department of Hematology, Dongyang People’s Hospital (Affiliated Dongyang Hospital of Wenzhou Medical University)

Abstract

Background: Chimeric antigen receptor (CAR) T-cell therapy can produce durable remission in refractory hematologic malignancies, but the expanding survivor population has focused attention on second primary malignancies (SPMs). Interpretation is difficult because recipients already carry substantial age-, disease-, and treatment-related cancer risk; follow-up is often short; outcome definitions vary; and competing mortality is high.

Main body: This critical review integrates epidemiologic, genomic, mechanistic, and regulatory evidence into a causal framework. Available evidence is consistent with a multistep clonal-evolution model: pre-existing clonal hematopoiesis and cumulative genotoxic injury establish the substrate; lymphodepletion, marrow inflammation, regenerative stress, and altered immune surveillance modify clonal fitness; and additional events permit transformation. Therapy-related myeloid neoplasms are the most actionable subgroup. By contrast, T-cell malignancies derived from CAR-modified cells are exceptionally rare and require direct lineage and vector analysis because detection of a CAR sequence alone does not prove insertional oncogenesis. We propose a graded attribution ladder and a risk-adapted surveillance pathway centered on serial blood counts, prompt evaluation of unexplained cytopenias or lymphoid abnormalities, age-appropriate cancer screening, and mechanism-specific molecular testing.

Conclusion: Temporal association should not be equated with causation. Prospective denominator-based cohorts, matched comparators, paired biospecimens, integration-site mapping, and single-cell lineage reconstruction are needed to distinguish background risk, treatment-associated clonal selection, and true product-related oncogenesis.

Related

  1. 454 Second primary hematologic malignancies in melanoma survivors before and after the introduction of immune checkpoint inhibitors: a population-based SEER analysis
    Jeffrey Afrifa-Yamoah, Damilola Ologbe, Duresha Malik +5
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYImmunologyOncologyDOAJ
  2. Chimeric antigen receptor T cell therapy targeting CD94 for cytotoxic T/NK cell malignancies
    C. C. Le, J. Weng, J. Liu +26
    bioRxivPreprintAll rights reservedFull textImmunologybioRxiv
  3. CAR-T cell therapy in hematology malignancies: breaking barriers, engineering the future
    Cynthia Aracely Alvizo-Báez, Ana Karina Chavez-Escamilla, Santiago Saavedra-Alonso +4
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyCrossref
  4. Intelligent immunotherapy: AI-driven optimization of CAR-T therapy in hematologic malignancies
    Farshid Farhadzadeh, Amirhossien Borji, Cena Aram +3
    iSciencePeer-reviewedCC BY-NC-ND 4.0Full textImmunologyCell PressCrossrefEurope PMC
  5. Circulating tumor DNA for prognosis in hematologic malignancies receiving immune checkpoint inhibitors or chimeric antigen receptor T-cell therapy: a systematic review and meta-analysis
    Congcong Wang, Zhibing Jiang, Jiaojiao Qiao +5
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
BibTeX
@article{huang2026second,
  title = {{Second primary malignancies after CAR T-cell therapy: causal attribution, clonal evolution, and risk-adapted surveillance}},
  author = {Sihui Huang and Yang Jin and Panruo Jiang and Gongqiang Wu},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = nov,
  doi = {10.3389/fimmu.2026.2014066},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.2014066/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Second primary malignancies after CAR T-cell therapy: causal attribution, clonal evolution, and risk-adapted surveillance
AU  - Sihui Huang
AU  - Yang Jin
AU  - Panruo Jiang
AU  - Gongqiang Wu
PY  - 2026
DA  - 2026/11/16
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.2014066
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.2014066/full
AB  - Background: Chimeric antigen receptor (CAR) T-cell therapy can produce durable remission in refractory hematologic malignancies, but the expanding survivor population has focused attention on second primary malignancies (SPMs). Interpretation is difficult because recipients already carry substantial age-, disease-, and treatment-related cancer risk; follow-up is often short; outcome definitions vary; and competing mortality is high.  Main body: This critical review integrates epidemiologic, genomic, mechanistic, and regulatory evidence into a causal framework. Available evidence is consistent with a multistep clonal-evolution model: pre-existing clonal hematopoiesis and cumulative genotoxic injury establish the substrate; lymphodepletion, marrow inflammation, regenerative stress, and altered immune surveillance modify clonal fitness; and additional events permit transformation. Therapy-related myeloid neoplasms are the most actionable subgroup. By contrast, T-cell malignancies derived from CAR-modified cells are exceptionally rare and require direct lineage and vector analysis because detection of a CAR sequence alone does not prove insertional oncogenesis. We propose a graded attribution ladder and a risk-adapted surveillance pathway centered on serial blood counts, prompt evaluation of unexplained cytopenias or lymphoid abnormalities, age-appropriate cancer screening, and mechanism-specific molecular testing.  Conclusion: Temporal association should not be equated with causation. Prospective denominator-based cohorts, matched comparators, paired biospecimens, integration-site mapping, and single-cell lineage reconstruction are needed to distinguish background risk, treatment-associated clonal selection, and true product-related oncogenesis.
SN  - 1664-3224
ER  -